Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Malignant Pleural Effusion: early-phase trial registry
3 of 5 indexed Malignant Pleural Effusion trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #3,391 of 28,707 conditions by registered trial count.
5 US clinical trials · 3 currently recruiting · #3,391 of 28,707 conditions by registered trial count
Malignant Pleural Effusion: 5 US clinical trials tracked, 3 recruiting.
Malignant Pleural Effusion is the subject of 5 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most active sponsor is David Bartlett, MD, running 1 of these trials.
Enrollment posture brief
Registry condition malignant-pleural-effusion
OPEN 3 | RECR 60% | LATE 0 | EARLY 4 | RANK #3391 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Acute Kidney Injury (AKI) (60% recruiting · 5 trials)
Malignant Pleural Effusion lists 3 open slots (60% of 5 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Malignant Pleural Effusion on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Malignant Pleural Effusion is recruiting above its size-band peers.
3 of 5 indexed trials (60%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Malignant Pleural Effusion research.
David Bartlett, MD accounts for 1 of 5 trials (20%). 5 distinct sponsors appear on at least one study for this condition label.
-
Malignant Pleural Effusion research is mostly interventional.
4 interventional and 1 observational studies make up this index (80% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
5 total, page 1 of 1
UNC Pleural Fluid Registry
UNC Lineberger Comprehensive Cancer Center
NCT05620329
Tocilizumab Delivered Via Pleural and Peritoneal Catheters in Patients With Advanced Metastatic Cancer
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
NCT06016179
Fast TILs to Treat Metastatic Cancer Patients With Pleural Disease
David Bartlett, MD
NCT07192900
Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
University of Chicago
NCT02122185
Bortezomib Plus Gemcitabine and Carboplatin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
NCT00052338
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Malignant Pleural Effusion records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Malignant Pleural Effusion trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Malignant Pleural Effusion page
5 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 3 Malignant Pleural Effusion trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- David Bartlett, MD sponsors the most Malignant Pleural Effusion trials on record, review their full trial history before evaluating a specific study. See David Bartlett, MD's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Malignant Pleural Effusion condition card totals 5 registered trials; most-linked intervention gemcitabine hydrochloride; top US site state Pennsylvania. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.